GLP-1 vs GIP vs Glucagon: What Each Receptor Actually Does

You have probably heard the names by now. Ozempic. Mounjaro. Retatrutide. These drugs are changing how we think about weight loss, diabetes, and metabolic health. But here is something most people never get a clear answer on: what do these drugs actually do at the biological level?

They all work by targeting hormone receptors. Specifically, three of them: GLP-1, GIP, and glucagon. Each receptor does something different. And the more receptors a drug targets, the more powerful the effect tends to be.

Let's break it down simply, starting from the beginning.

First, What Is a Hormone Receptor?

Think of a hormone receptor like a lock on a cell's surface. The hormone is the key. When the right key fits the lock, the cell gets a signal telling it what to do — release insulin, slow digestion, burn more fat, or something else entirely.

GLP-1, GIP, and glucagon are all hormones your body naturally produces. They are part of a system called the incretin system, which regulates blood sugar, appetite, and energy metabolism. The drugs we are talking about are designed to mimic or amplify these natural hormones — sometimes all three at once.

GLP-1: The Appetite Suppressor

GLP-1 stands for glucagon-like peptide-1. Your gut releases it after you eat. It does three main things:

• Tells your pancreas to release insulin — which lowers blood sugar after a meal
• Slows gastric emptying — food moves more slowly from your stomach to your intestines, so you feel full longer
• Signals your brain to reduce appetite — GLP-1 receptors in the hypothalamus directly reduce hunger signals

This is why GLP-1 drugs like semaglutide (Ozempic, Wegovy) are so effective. They essentially keep your body in a prolonged post-meal state — less hungry, slower digestion, better blood sugar control.

The key insight: GLP-1 does not just suppress appetite. It resets the brain's hunger thermostat. People on GLP-1 drugs often report that food simply stops being as interesting. That is the receptor working exactly as designed.

Semaglutide is a pure GLP-1 receptor agonist. It targets this one receptor very effectively, which is why it produces 10-15% average body weight loss in clinical trials. You can read the full profile on our Semaglutide peptide page.

GIP: The Forgotten Partner

GIP stands for glucose-dependent insulinotropic polypeptide. It is the other major incretin hormone, and for a long time researchers thought it was not very useful for weight loss. In fact, early research suggested that activating GIP receptors might even cause weight gain.

That thinking turned out to be wrong — or at least incomplete.

When GIP is activated alongside GLP-1, something interesting happens. The two receptors work synergistically. GIP amplifies the insulin response, improves how fat cells handle glucose, and appears to reduce some of the nausea that GLP-1 agonists can cause on their own. The combination is more powerful than either receptor alone.

Here is what GIP receptor activation does:

• Enhances insulin secretion — works alongside GLP-1 to improve blood sugar control
• Improves fat cell metabolism — GIP receptors on fat cells help regulate how fat is stored and released
• Reduces GLP-1 side effects — the combination appears to reduce nausea and GI discomfort compared to GLP-1 alone
• Bone and muscle effects — emerging research suggests GIP may also play a role in bone density and lean mass preservation

Tirzepatide (Mounjaro, Zepbound) is the first approved drug to target both GLP-1 and GIP simultaneously. This dual action is why it outperforms semaglutide in head-to-head trials, producing 15-22% average body weight loss. See the full breakdown on our Retatrutide vs. Tirzepatide comparison page.

Glucagon: The Metabolic Accelerator

Glucagon is the one most people have not heard of — and it is the most counterintuitive piece of this puzzle.

Glucagon is usually thought of as the opposite of insulin. When blood sugar drops, glucagon tells the liver to release stored glucose. It raises blood sugar. So why would you want to activate glucagon receptors in a weight loss drug?

The answer is that glucagon does something else that is incredibly valuable for weight loss: it increases energy expenditure.

Glucagon receptor activation in the liver and fat tissue:

• Boosts basal metabolic rate — your body burns more calories at rest
• Increases fat oxidation — the liver breaks down fat (lipolysis) more aggressively
• Reduces liver fat — glucagon is particularly effective at clearing fat from the liver (hepatic steatosis), which is a major issue in metabolic disease
• Suppresses appetite via the brain — glucagon also has direct appetite-suppressing effects in the hypothalamus

The challenge with glucagon is that activating it alone raises blood sugar — exactly what you do not want in a diabetic or metabolically compromised patient. But when glucagon is activated together with GLP-1 and GIP, the insulin-stimulating effects of GLP-1 and GIP counterbalance the blood sugar-raising effect of glucagon. You get the metabolic acceleration without the blood sugar spike.

Think of it this way: GLP-1 is the brake pedal for appetite. GIP is the co-pilot that makes the brakes work better. Glucagon is the engine that burns more fuel while you are braking. Together, you slow down eating AND speed up burning.

How the Three Receptors Stack Up

Why More Receptors Generally Means More Weight Loss

This is the key insight that explains the progression from Ozempic to Mounjaro to Retatrutide:

• Semaglutide (GLP-1 only): ~10-15% body weight loss in trials
• Tirzepatide (GLP-1 + GIP): ~15-22% body weight loss in trials
• Retatrutide (GLP-1 + GIP + Glucagon): ~16.8% in Phase 3 diabetes trial, with weight loss still ongoing at trial end — obesity-specific trials expected to show even higher numbers

Each additional receptor adds a new mechanism. More mechanisms means the drug can attack the problem from more angles simultaneously. Appetite suppression, metabolic acceleration, fat oxidation, blood sugar control — all happening at once.

You can read the full Phase 3 data and mechanism breakdown on our Retatrutide peptide page.

Does This Mean Retatrutide Is Always Better?

Not necessarily. More receptors also means more complexity — and potentially more side effects. The glucagon component in Retatrutide is still being studied for long-term effects. Tirzepatide has a longer safety track record and is already FDA-approved. Semaglutide has the most real-world data of any of these compounds.

The right drug depends on your specific situation: your metabolic health, your goals, your tolerance for side effects, and what your doctor recommends. What this science tells us is that the mechanism matters — and understanding which receptors a drug targets helps you have a much more informed conversation with your healthcare provider.

What About the Research Peptide Versions?

It is worth noting that GLP-1, GIP, and glucagon receptor agonists also exist as research peptides outside the pharmaceutical approval process. Retatrutide, for example, is not yet FDA-approved and is currently in Phase 3 trials. Research versions of these compounds are available through research channels but are not approved for human use, and anyone considering them should do so with full awareness of the regulatory status and the importance of medical oversight.

At Peptide Insights, we track all of these compounds closely — both the approved drugs and the emerging research peptides — because understanding the science is the first step to making informed decisions about your health.

The Bottom Line

Here is the plain-language summary:

• GLP-1 tells your brain you are full and tells your pancreas to release insulin. It is the foundation of all modern weight loss drugs in this class.
• GIP amplifies GLP-1's effects, improves fat metabolism, and reduces side effects. Adding it to GLP-1 is why Tirzepatide outperforms Semaglutide.
• Glucagon is the metabolic accelerator. It makes your body burn more calories and fat. Adding it to GLP-1 and GIP is what makes Retatrutide potentially the most powerful compound in this class.

The science here is genuinely exciting. We are watching the development of drugs that work with your body's own hormonal systems to produce results that were previously only achievable with surgery. And we are just getting started.

Explore Further

• Semaglutide: Full Peptide Profile
• Retatrutide: Phase 3 Data and Mechanism
• Retatrutide vs. Tirzepatide: Full Comparison
• Why Retatrutide Could Be the Weight Loss Breakthrough You've Been Waiting For

References

1. Drucker DJ. "The biology of incretin hormones." Cell Metabolism, 2006. PubMed
2. Finan B, et al. "Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans." Science Translational Medicine, 2013. PubMed
3. Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine, 2023. NEJM
4. Eli Lilly and Company. "Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial." investor.lilly.com
5. Nauck MA, Meier JJ. "Incretin hormones: Their role in health and disease." Diabetes, Obesity and Metabolism, 2018. PubMed